# Acumen Pharmaceuticals, Inc.: overview

ABOS · Nasdaq · CIK 1576885 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/abos.md) · [Financials](/companies/abos/financials.md) · [Filings](/companies/abos/filings.md) · [Insiders](/companies/abos/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | not reported | [(0.48)](/filings/0001628280-26-034204.md) | [(0.68)](/filings/0001628280-26-056199.md) | [(0.44)](/filings/0001628280-26-067276.md) | not reported | [(0.33)](/filings/0001628280-26-034204.md) | [(0.45)](/filings/0001628280-26-056199.md) | [(0.35)](/filings/0001628280-26-067276.md) |
| Free cash flow | $m | [(27.2) d](/filings/0001628280-26-021413.md) | [(34.2)](/filings/0001628280-26-034204.md) | [(31.8) d](/filings/0001628280-26-056199.md) | [(30.5) d](/filings/0001628280-26-067276.md) | [(19.1) d](/filings/0001628280-26-021413.md) | [(24.1)](/filings/0001628280-26-034204.md) | [(18.1) d](/filings/0001628280-26-056199.md) | [(26.7) d](/filings/0001628280-26-067276.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(5.02)](/filings/0001576885-23-000017.md) | [(1.06)](/filings/0001576885-24-000047.md) | [(1.08)](/filings/0001576885-25-000049.md) | [(1.71)](/filings/0001628280-26-021413.md) | [(2.00)](/filings/0001628280-26-021413.md) |
| Free cash flow | $m | [(18.0)](/filings/0001576885-23-000017.md) | [(35.3)](/filings/0001576885-24-000047.md) | [(43.1)](/filings/0001576885-25-000049.md) | [(86.2)](/filings/0001628280-26-021413.md) | [(116)](/filings/0001628280-26-021413.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/abos/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $56.1m | 20,992,669 |  | Unchanged |
| [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $9.9m | 3,720,105 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.6m | 2,490,115 |  | Added +2,311,789 |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $6.6m | 2,454,754 |  | Unchanged |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $6.2m | 2,305,096 |  | Unchanged |
| [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $5.6m | 2,111,334 |  | Reduced −45,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.5m | 1,672,072 |  | Added +165,795 |
| [Knollwood Investment Advisory, LLC](/funds/1999346.md) | 2026-06-30 | $4.3m | 1,628,510 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.0m | 1,141,858 |  | Added +725,620 |
| [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $2.8m | 1,053,797 |  | Unchanged |

## Recent filings

[All 361 filings](/companies/abos/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-26 | 16:03 ET | [10-Q](/filings/0001628280-26-067276.md) | Quarterly report, period 2026-09-30 | 0001628280-26-067276 |
| 2026-10-26 | 07:09 ET | [8-K](/filings/0001628280-26-067129.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-067129 |
| 2026-09-16 | 09:26 ET | [8-K](/filings/0001628280-26-062137.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-062137 |
| 2026-08-12 | 16:13 ET | [10-Q](/filings/0001628280-26-056199.md) | Quarterly report, period 2026-06-30 | 0001628280-26-056199 |
| 2026-08-12 | 07:02 ET | [8-K](/filings/0001628280-26-055940.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-055940 |
| 2026-06-16 | 07:34 ET | [8-K](/filings/0001628280-26-043416.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-043416 |
| 2026-06-03 | 16:43 ET | [8-K](/filings/0001628280-26-040447.md) | 5.07 Shareholder vote results | 0001628280-26-040447 |
| 2026-05-12 | 17:16 ET | [10-Q](/filings/0001628280-26-034204.md) | Quarterly report, period 2026-03-31 | 0001628280-26-034204 |
| 2026-05-12 | 07:07 ET | [8-K](/filings/0001628280-26-033868.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-033868 |
| 2026-04-23 | 16:30 ET | [DEF 14A](/filings/0001628280-26-026870.md) | Proxy statement, period 2025-12-31 | 0001628280-26-026870 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-021413.md), filed Mar 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1576885
- Tickers: ABOS
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 07:07 ET. No prices; not investment advice.